Paige Earns CE-IVD and UKCA Marks for Clinical AI Application to Detect Breast Cancer Metastases in Lymph Nodes
Paige,a global leader in clinical AI applications in pathology, today announced it received CE-IVD and UKCA marks for Paige Breast Lymph Node. The newly launched AI medical device software helps pathologists detect if breast cancer has metastasized to lymph nodes, concurrent with pathologists’ own interpretive review. With the CE-IVD and UKCA designations, laboratories and hospitals in the European Economic Area, Switzerland and the UK can now use the product in the course of clinical diagnosis.*
“Paige’s aim is to provide pathologists with innovative, care enhancing technology so they can provide the best possible insights to patients. Through Paige Breast Lymph Node, pathologists can more efficiently identify tumor metastases of any size, including small micrometastases,” said Juan Retamero, M.D., Medical Director, Digital Pathology Transformation at Paige. “The CE-IVD and UKCA marks for Paige Breast Lymph Node are a vital step towards increasing the adoption of our new tool in European hospitals and laboratories.”
Paige Breast Lymph Node uses the same underlying AI technology as Paige Prostate and can be deployed in any laboratory or hospital setting that is on the Paige Platform.
For more information about Paige Breast Lymph Node, visit http://info.paige.ai/breast or contact info@paige.ai.
*Paige Breast Lymph Node is available for “Research Use Only” in the United States, not for use in diagnostic procedures.
About Paige
Paige was founded in 2017 by Thomas Fuchs, Dr.Sc., David Klimstra, M.D., and colleagues from Memorial Sloan Kettering Cancer Center (MSK). The company builds computational pathology products designed so patients and their care teams can make effective, more informed treatment decisions. With this new class of AI-based technologies positioned to drive the future of diagnostics, Paige created a platform to deliver this novel technology to pathologists to transform their workflow and increase diagnostic confidence and productivity. Paige’s products deliver insights to pathologists and oncologists so they can arrive efficiently at more precise diagnoses for patients. Paige is the first company to receive FDA approval for an AI-based digital pathology product.
For additional information, please visit: https://www.paige.ai, Twitter and LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220406005362/en/
Contact information
Jon Yu
ICR Westwicke
Tel: 475.395.5375
Jon.Yu@westwicke.com
About Business Wire
Business WireSubscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member10.5.2024 17:45:00 CEST | Press release
EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD,MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. “We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience. The appointment of Dr Motlagh is critical for Egle, as the company is moving to clinical development of assets in oncology and auto-immunity. Pejvack will impact the future development of the rich pipeline at Egle, based on the modulation of regulatory T cells. As we advance toward the clinical development of EGL-001, John’s expertise in business development in the field of oncology is instrumental for us to successfully execute on our strategic priorities.” said Vincent Brichard, M.D., EGLE’s Interim CEO and Board member. “I am excited to join Egle Therapeutics to translate into the cl
HighRadius Named 2024 Gartner ® Magic Quadrant™ Leader for the Third Time in a Row10.5.2024 16:00:00 CEST | Press release
HighRadius, the leading provider of the Autonomous Finance Platform for the office of the CFO, has once again been named a Leader in the 2024 Gartner Magic Quadrant for Invoice-to-Cash Applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240510668572/en/ HighRadius Named 2024 Gartner® Magic Quadrant™ Leader for the Third Time in a Row (Graphic: Business Wire) Gartner Magic Quadrant gives enterprise technology shoppers an unbiased assessment of how well-competing providers are performing against Gartner’s market view and is supplemented by validated user reviews. According to Gartner, “Leaders execute well against their current vision and are well positioned for tomorrow.” This is the third consecutive year for HighRadius to be placed as a leader on the report. “We're honored to be recognized for our maniacal focus on invoice-to-cash business outcome improvements - DSO, Bad Debt, Interchange Fees, & Productivity,” sai
The Ministry of Investment of Saudi Arabia (MISA) Signs MoU with Ant International to Expand Business in Saudi Arabia, Supporting Regional Digital Innovation10.5.2024 15:36:00 CEST | Press release
The Ministry of Investment of Saudi Arabia (MISA) has signed a Memorandum of Understanding (MoU) with Ant International, to facilitate the business expansion into the Kingdom. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507130337/en/ (Photo: Business Wire) Ant International’s President, Douglas Feagin, met with Mr. Eng Saleh Khabti, Deputy Minister of Investment of Saudi Arabia during a signing ceremony held in Riyadh, to welcome the new partnership and sign an agreement outlining shared goals for technological innovation and economic growth opportunities in Saudi Arabia. Through this partnership, MISA welcomes and supports Ant International’s expansion plan to establish an entity in Saudi Arabia, enabling assistance when acquiring licences and certificates to expand and enhance its service offerings. Ant International will use Saudi Arabia as a key gateway into the Middle East to further expand the reach of its paymen
Wipro Appoints Vinay Firake as Chief Executive Officer for APMEA Strategic Market Unit10.5.2024 15:11:00 CEST | Press release
Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading technology services and consulting company, today announced the appointment of Vinay Firake as the Chief Executive Officer, APMEA (Asia Pacific, India, Middle East & Africa) Strategic Market Unit (SMU), effective immediately. Vinay will report to Srini Pallia and will also join the Wipro Executive Board. Vinay has been with Wipro for 26 years and has grown with the organization, serving in various leadership roles. He was most recently the Senior Vice President and Managing Director of Wipro-Nordics Business Unit based in Stockholm, where he led Operations across all industries and services. Prior to that, he led the Manufacturing & Automotive Business Unit in Europe and held various roles spanning Europe and North America, including Global Head for the Enterprise Digital Operations & Platforms business and Sales Head for Wipro's Enterprise Applications businesses in Europe. “Vinay has successfully led Wipro in diverse regio
Kolmar BNH, a Top-Tier Korean Enterprise Specializing in the Production of HemoHIM, Dedicates over 2% of its Annual Sales to R&D10.5.2024 15:00:00 CEST | Press release
Kolmar BNH (KOSDAQ: 200130), a manufacturer of HemoHIM, a health-enhancing functional food, has emerged as a frontrunner in the global Original Development Manufacturing (ODM) market, owing to its pioneering investments in research and development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240510895890/en/ A researcher from Kolmar BNH Health Food Lab. (Photo: Kolmar BNH) Founded in 2005, Kolmar BNH is an ODM company for health-functional food products. ODM enterprises, encompassing various sectors from trend analysis to R&D, product conceptualization, manufacturing, and quality assurance, cater to customers with entrepreneurial aspirations. This framework facilitates opportunities for individuals with a passion for business and ideas. The cornerstone of Kolmar BNH's competitiveness lies in its technological adeptness, underpinned by substantial R&D investments. The company annually allocates over 2% of its sales revenue
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom